Total Funding
4
25
Total FundingDebt Financing raised
Growth Score 4 in past quarter
-15 pts
Heat Score 25 in past quarter
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1200740
Kadmus Pharmaceuticals, Inc., a biopharmaceutical company, commercially exploits endocannabinoid pathways to develop therapeutics.
- Kelvin Gee: Founder
About the Company
Kadmus Pharmaceuticals, Inc., a biopharmaceutical company, commercially exploits endocannabinoid pathways to develop therapeutics. Endocannabinoids are naturally occurring signaling molecules, whose functions include regulating mood, pain, and metabolism. It offers a portfolio of compounds with activity against a range of disorders targeting CNS
conditions, metabolic disorders, neuropathic pain, and obesity. The company develops products for various conditions through the inhibition of endocannabinoid degradation and activation of endocannabinoid related pathways and peripheral cannabinoid receptors. It operates in the United States, Canada, and Europe. Kadmus Pharmaceuticals, Inc. was founded in 1998 and is based in Irvine, California.

